VX680 suppresses the growth of HepG2 cells and enhances the chemosensitivity to cisplatin

Oncology Letters

Volumn 7, Issue 1, 2014, Pages 121-124

  Yao, Rucheng ^a   Zheng, Jun ^a   Zheng, Weihong ^a   Gong, Yuan ^a   Liu, Wei ^a   Xing, Rongchun ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Aurora A; Chemosensitivity; Cisplatin; HepG2 cells; VX680

Indexed keywords

CISPLATIN; PROTEIN BCL 2; PROTEIN P53; TOZASERTIB;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEPG2; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84888398976     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1648     Document Type: Article

References (20)

1. Nathan H, Segev DL, Mayo SC, Choti MA, Cameron AM, Wolfgang CL, Hirose K, Edil BH, Schulick RD and Pawlik TM: National trends in surgical procedures for hepatocellular carcinoma: 1998-2008. Cancer 118: 1838-1844, 2012.
2. Carmena M and Earnshaw WC: The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4: 842-854, 2003.
3. Zhang XH, Rao M, Loprieato JA, et al: Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 7: 1388-1397, 2008.
4. Lam AK, Ong K and Ho YH: Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity. Hum Pathol 39: 599-604, 2008.
5. Lee EC, Frolov A, Li R, Ayala G and Greenberg NM: Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 66: 4996-5002, 2006.
6. Terakawa T, Miyake H, Kumano M and Fujisawa M: Growth inhibition and enhanced chemosensitivity induced by down-regulation of Aurora-A in human renal cell carcinoma Caki-2 cells using short hairpin RNA. Oncol Lett 2: 713-717, 2011.
7. Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y and Tanaka H: Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 95: 611-619, 2008.
8. Kuang Y, Cai J, Li D, Han Q, Cao J and Wang Z: Repression of Dicer is associated with invasive phenotype and chemoresistance in ovarian cancer. Oncol Lett 5: 1149-1154, 2013.
9. Park HS, Park WS, Bondaruk J, et al: Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 100: 1401-1411, 2008.
10. Wang XX, Liu R, Jin SQ, Fan FY and Zhan QM: Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line. Cell Res 16: 356-366, 2006.
11. Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A, Persky DO, Miller TP and Mahadevan D: Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 81: 881-890, 2011.
12. Shimomura T, Hasako S, Nakatsuru Y, et al: MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 9: 157-166, 2010.
13. Harrington EA, Bebbington D, Moore J, et al: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10: 262-267, 2004.
14. Fiskus W, Wang Y, Joshi R, et al: Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 14: 6106-6115, 2008.
15. Jin ZJ: Addition in drug combination. Zhongguo Yao Li Xue Bao 1: 70-76, 1980 (In Chinese).
16. Jeng YM, Peng SY, Lin CY and Hsu HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10: 2065-2071, 2004.
17. Lin ZZ, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, Lee PH, Cheng AL and Hsu HC: Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer 10: 461, 2010.
18. Lin ZZ, Hsu HC, Hsu CH, et al: The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 50: 518-527, 2009.
19. Yu Y, Zhang Y, Hu J, et al: MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma. Cancer Sci 103: 716-722, 2012.
20. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA and Sen S: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36: 55-62, 2004.